Home / Investors / Overview

Company Information

CymaBay Therapeutics (NASDAQ: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.  In addition to evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH), our phase 3 ready program for arhalofenate in gout has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018


CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update


CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15

Upcoming Event

Jun 5 2018 9:00 am PT

Annual Meeting of Stockholders

June 5, 2018 at 9:00 am PT

Pacific Research Center, 7677 Gateway Blvd., Conference Center 2nd Floor, Apex Room, Newark, CA 94560

Q4 2017 Quarterly Results